Table 2 Correlation between Braf/p300 staining and AJCC stage in 327 melanoma patients
From: A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma
| Â | Stage I | Stage II | Stage III | Stage IV | p-value* |
|---|---|---|---|---|---|
Braf | Â | Â | Â | Â | Â |
Low | 37 (46.3%) | 26 (23.0%) | 11 (20.0%) | 20 (25.3%) | 9.8 × 10-4 |
High | 43 (53.8%) | 87 (77.0%) | 44 (80.0%) | 59 (74.7%) | Â |
Nuclear p300 | Â | Â | Â | Â | Â |
Low | 29 (36.3%) | 47 (41.6%) | 30 (54.5%) | 33 (41.8%) | 0.204 |
High | 51 (63.7%) | 66 (58.4%) | 25 (45.5%) | 46 (59.2%) | Â |
Cytoplasmic p300 | Â | Â | Â | Â | Â |
Low | 48 (60.0%) | 53 (46.9%) | 17 (30.9%) | 36 (45.6%) | 0.011 |
High | 32 (40.0%) | 60 (53.1%) | 38 (69.1%) | 43 (54.4%) | Â |
Braf and nuclear p300 | Â | Â | Â | Â | Â |
Low braf low p300 | 11 (13.8%) | 13 (11.5%) | 6 (10.9%) | 6 (7.6%) | 0.010 |
Low braf high p300 | 26 (32.5%) | 14 (12.4%) | 6 (10.9%) | 16 (20.3%) | Â |
High braf low p300 | 18 (22.5%) | 34 (30.1%) | 24 (43.6%) | 27 (34.2%) | Â |
High braf high p300 | 25 (31.3%) | 52 (46.0%) | 19 (34.6%) | 30 (38.0%) | Â |
Braf and cytoplasmic p300 | Â | Â | Â | Â | Â |
Low braf low p300 | 21 (26.3%) | 19 (16.8%) | 5 (9.1%) | 7 (8.8%) | 8.7 × 10-5 |
Low braf high p300 | 16 (20.0%) | 7 (6.2%) | 6 (10.9%) | 13 (16.5%) | Â |
High braf low p300 | 27 (33.7%) | 34 (30.1%) | 12 (21.8%) | 29 (36.7%) | Â |
High braf high p300 | 16 (20.0%) | 53 (46.9%) | 32 (58.2%) | 30 (38.0%) | Â |